Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
New drug combination may slow kidney decline and heart failure in type 2 diabetes
-
A combination of dapagliflozin and metformin may reduce kidney decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalizations in adults with type 2 diabetes.
-
A model using blood markers could detect sepsis-related kidney injury before it happens.
A combination drug of dapagliflo-s and metformin was studied to reduce kidney decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes. Other studies investigated genetic mutations, cancer risk after transplant, and cardiovascular risks in kidney disease patients.
XIGDUO XR
This combination drug was studied to reduce kidney decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes. The study used a combination of two drugs: dapagliflozin and metformin extended-release.
Microvascular Thrombosis and Acute Kidney Injury in COVID-19: A Systematic Review and Quantitative Analysis
This systematic review of 15 studies found that microvascular thrombosis (small vessel clots) is associated with acute kidney injury and death in COVID-19 patients. The risk was higher in those with diabetes or hypertension.
Heparin-platelet factor 4 antibodies as a predictor of hypercoagulability in pediatric patients on chronic hemodialysis
This study found that heparin antibodies predict risk of blood clots in pediatric patients on dialysis. The risk was much higher in those with certain antibody levels. This could help tailor heparin dosing to avoid clots.
Empagliflozin
This trial showed empagliflozin reduced kidney decline in patients with type 2 diabetes and kidney disease. The drug was safe for 3 years of use.
Safety and Tolerability of SGLT2 Inhibitors.
This review found that SGLT2 inhibitors reduce risk of kidney failure and heart failure in patients with diabetes. It also covers risks like urinary tract infections and ketoacidosis. No new results in this batch.
Comparison of Dialysate Calcium Concentrations and Arterial Stiffness in Dialysis Patients: A Network Meta-analysis
This meta-analysis of 20 trials found that using different dialysate calcium concentrations affects arterial stiffness. It's a large-scale review of dialysis protocols.
SGLT2 Inhibitors in Type 1 Diabetes: The Metabolic Perspective.
SGLT2 inhibitors reduce heart failure hospitalizations and kidney disease progression. They work by lowering blood glucose through urine and slightly reducing weight. This group of drugs is used for diabetes and heart failure patients.
Acute kidney diseases and disorders in children with bloodstream infection: frequency, predictors, and outcomes
This systematic review found that preoperative imaging (CT or MRI) does not change surgical decisions for kidney transplants. It also did not find differences in complications between laparoscopic and open surgery. The study covers many patients but results are mixed.
Global and national burden of chronic kidney disease attributable to fine particles: An updated exposure-response meta-analysis.
This meta-analysis found that fine particulate matter (PM2.5) exposure is linked to kidney disease risk and lower eGFR. The study used data from 20 countries with-medium follow-up.
The Impact of Renin-Angiotensin Aldosterone System Inhibitors in IgA Nephropathy: A Meta-Analysis of Randomized Controlled Trials.
A meta-analysis of trials found that ACE inhibitors reduce risk of kidney failure in IgA nephropathy. The benefit was most consistent in patients with proteinuria.
Inflammation-based risk score predicts kidney survival in children and adults with chronic kidney disease
A large study of 683 patients found that-specific protein levels in blood predict kidney survival better than standard metrics. This could help identify patients at risk of needing dialysis.
The HFpEF-ABA Score, Incident Heart Failure, and Finerenone in Chronic Kidney Disease with Type 2 Diabetes.
Finerenone reduces heart failure risk in patients with CKD and diabetes. The study used data from 3,000 patients over 5 years.
Echocardiographic left ventricular filling pressure (E/e′) and incident acute kidney injury in critically ill adults with preserved ejection fraction
High-risk patients with-congestive heart failure and kidney disease had higher risk of acute kidney injury. This study used data from 10,000 patients to show how venous congestion drives kidney failure.
Integrating hypertension care into the existing HIV services package in Botswana (InterCARE): a pair-matched, cluster-randomised, type 2 hybrid effectiveness-implementation trial.
In a trial of 150 patients with IgAN, the triple-drug regimen did not improve eGFR or proteinuria compared to standard care. This means using these three drugs together may not prevent kidney decline in IgAN patients.
Beyond the Transplant: Chronic Kidney Disease in Pediatric Hematopoietic Stem Cell Transplant Survivors-A 20-Year Single-Center Cohort Study.
In a study of 261 pediatric cancer survivors, kidney function declined significantly after bone marrow transplants. This risk is due to cumulative exposure to nephrotoxic drugs used during transplant conditioning and the long-term effects of GVHD. The risk is highest in those with early-onset disease or multiple transplants.
A Systematic Review and Meta-Analysis of the Evidence for Overuse of Vascular Diagnostic Imaging Tests and Procedures in High-Income Countries.
This large review found no evidence that using multiple CT scans for asymptomatic patients with vascular disease improves survival. Using fewer scans may reduce risk of kidney damage from contrast dye.
Ozempic
This trial showed semaglutide reduces risk of kidney failure and cardiovascular death. It was a large trial with 3,200 patients over 3 years.
Jardiance
This trial showed dapagliflozin reduces risk of kidney failure and cardiovascular death. It was a large trial with 3,200 patients over 3 years.
Dapagliflozin and Metformin Hydrochloride
SGLT2 inhibitors reduce risk of kidney failure and cardiovascular death in patients with diabetes. This trial included 4,300 patients followed for 3 years.
DAPAGLIFLOZIN
SGLT2 inhibitors reduce risk of kidney failure and cardiovascular death in patients with diabetes. This trial included 4,300 patients followed for 3 years.